We use essential cookies to run this site and cookie-free visitor statistics, which you can switch off. Marketing cookies only with your consent. Cookie policy

EssentialAlways on

Keep the site secure and working, and remember your cookie choice.

Visitor statistics

Cookie-free counts of which pages are used and how fast they load, so we can improve them. On unless you switch it off.

Marketing

Measure our campaigns on other sites, such as LinkedIn. Off until you allow it.

Press release · Long read

We make the only whole blood leukoreduction filter in the world without organic solvents or wastewater.

CellNet™ PR · Every batch

The footprint inside the filter

Sangtech Lab Inc.Published · 9 min read

Transfusion medicine is starting to measure its carbon cost. The one number the ledger keeps leaving out is how the filter itself is made. We think that is the next thing worth changing.

In brief

  • A 2024 life-cycle study put one red cell transfusion in England at 7.56 kg CO₂e. How the filter inside the pack was made is not itemized.
  • Conventional filter media are treated with organic solvents and process water. CellNet™ media is modified with patented supercritical CO₂ instead: no solvents, zero process water.
  • Nothing was traded away: fewer than 0.3×10⁶ residual white cells, red cell recovery above 92%, and 98–100% platelet removal.

Taipei, Taiwan, November 17, 2026. For thirty years, the leukocyte filter was treated as a solved problem. It removes white cells from donated blood, it meets the standard, and the industry moved on. The filter worked, so the question of how it is made was treated as finished too.

It is not finished. And the gap between how well these filters perform and how cleanly they are produced is wider than almost anyone realizes.

This is a long read about a small part. A single-use filter the size of your palm, made by the tens of millions every year, sitting quietly inside nearly every bag of donated blood in the developed world. It is one of the great unremarked successes of modern transfusion safety. It is also carrying an environmental cost that no one has been counting. Here is where that cost comes from, why it stays invisible, and what we did about it.

01How a filter gets its surface

Start with the fiber, because everything follows from it.

A leukoreduction filter is, at its heart, a mat of fine nonwoven polymer fiber. On its own, that fiber does not do the delicate work of letting red cells through while holding white cells back. It has to be given new surface properties first, so that the physics of wettability and surface charge do the sorting. How you give the fiber those properties is the entire craft of the filter.

For three decades, the commercial answer has been wet chemistry. You take a hydrophilic agent, you dissolve it in an organic solvent such as ethanol, acetone or tert-butanol, you apply it to the fiber by coating or grafting, and then you wash the excess away. It is a mature, well-understood, effective process. It is also, by its nature, a wet one.

The conventional routeWet chemistry, every production run
  1. 01DissolveHydrophilic agent in ethanol, acetone or tert-butanol
  2. 02ApplyCoat or graft onto the fiber
  3. 03WashRinse the excess away
  4. 04DryDrive off solvent and water
What leaves the lineSolventWash waterWastewaterDrying energy
Figure 1Solvent in, wash water through, wastewater out, drying energy on top. For a part that is used once.

None of that is a scandal. It is simply how the industry grew up, at a time when no one was asked to account for the solvent in the tank or the water down the drain. The filters got better and better. The way of making them stayed the same.

02The number that is missing

In 2024, the journal Transfusion published something the field had never had: a full life-cycle assessment of a red cell transfusion, measured across the blood service of an entire country. The headline figure was 7.56 kg of CO₂ equivalent per unit transfused in England and, scaled up, on the order of ten million kilograms of CO₂ equivalent a year for red cells alone.

It is a landmark study, and an overdue one. It counted transport. It counted the refrigeration that runs around the clock. It counted the plastic of the blood pack as a material. It did not, because almost no study yet does, count how the filter inside that pack was manufactured.

Carbon ledgerOne red cell unit, transfused in Englandkg CO₂e
  • Transportation2.80
  • Hospital transfusion processes1.90
  • Donation1.30
  • All other stages1.56
  • Total per unit7.56
  • How the filter in the pack was made: solvents, process water, wastewaterNot itemized

Central estimate. About 10.3 million kg CO₂e a year for red cells across England. Hibbs et al., Transfusion, 2024.

Figure 2The study counted transport, refrigeration and the blood pack as material. The making of the filter sits upstream, out of the ledger.

That is the pattern worth naming. When healthcare talks about the environmental cost of a transfusion, it tends to count the device as waste at the end of its life. It rarely counts the solvents and the wastewater that went into making the device at the start of its life. The manufacturing footprint sits upstream, in a factory, often in another country, long before a unit of blood is ever collected. It is out of sight, and so it stays out of the ledger.

Now put scale against it. The World Health Organization counts about 120 million blood donations collected worldwide each year. Across the high-income blood services where leukoreduction is standard practice, from the United States, where more than 95% of units are leukoreduced, to Canada, Japan and much of Europe, nearly every one of those units passes through a single-use leukocyte filter. That places global filter production in the tens of millions of units a year, each one, under the conventional method, carrying its small share of solvent and wastewater.

120 millionblood donations collected worldwide each year. Each dot is one million.

Small, multiplied by tens of millions, stops being small.

Figure 3Across high-income blood services, nearly every unit passes through a single-use leukocyte filter. Source: WHO.

03Why your biggest footprint is in your suppliers

There is a reason this matters now, beyond good intentions, and it is written into the way organizations are being asked to report.

For most institutions, the largest part of the carbon footprint is not in their own buildings and vehicles. It is in their supply chain, the goods and services they buy. Analyses by CDP and the Boston Consulting Group have put corporate supply-chain, or Scope 3, emissions at around 26 times operational emissions on average. In healthcare specifically, work by Health Care Without Harm and Arup found that about 71% of the sector’s climate footprint comes from its supply chain. Healthcare itself accounts for roughly 4.4% of global net greenhouse gas emissions.

Every sector, on average
26×Supply-chain (Scope 3) emissions compared with a company’s own operations
Own operationsSupply chain
Healthcare
71%of the health sector’s climate footprint comes from its supply chain
Figure 4The footprint that is hardest to move sits with suppliers. Sources: CDP and BCG, 2024; Health Care Without Harm and Arup, 2019.

Reporting frameworks are catching up to that reality. The IFRS S2 climate-disclosure standard brings Scope 3 into the picture. And the practical problem every disclosure team runs into is the same: supply-chain numbers are mostly estimates, built from industry averages, because a spend-based average cannot tell one supplier’s filter from another’s.

That is exactly where a measured, supplier-specific improvement becomes valuable. If the filter you buy is made without solvents and without process water, that is not a rounding error in an average. It is a real, attributable reduction in the part of your footprint that is hardest to move. For CellNet™ media, that reduction is more than 90% less process carbon at the media processing stage, 7.68 kg CO₂e per kg of media against 83.2 kg for conventional wet modification, with 0 L of process water. The data is in our supplier sustainability data pack, available on request.

04Water, the other half of the story

Carbon gets the attention, but the wet-chemistry route has a second cost that is easy to forget: water.

The dissolve-apply-rinse approach uses water to carry, to wash and to treat. The textile industry, which hydrophilizes fibers by the same wet-chemistry logic, is one of the most visible examples of what that adds up to at scale; by some estimates the dyeing and finishing of textiles accounts for close to a fifth of global industrial water pollution. Filter media are produced on a far smaller scale than textiles, but by the same underlying method, with the same need for process water and the same wastewater to treat afterwards.

When we talk about our own process, the water figure is not a percentage reduction. It is zero. No coating bath, no rinse, no process wastewater to treat.

  • 0Organic solventsNo solvent in the tank
  • 0Process waterNot reduced, not recycled
  • 0Process wastewaterNothing to treat

>90%Less process carbon7.68 kg CO₂e per kg of media, against 83.2 kg for conventional wet modification. Media processing stage, gate-to-gate; Sangtech’s own calculation.

Figure 5Water: a number that needs no baseline to mean something. Carbon: measured against conventional wet modification, with the method in our data pack.

05We went back to the fiber

CellNet™ PR is made differently, and we are deliberately guarded about exactly how, because the method is the heart of the company.

What we can say is this. Instead of dissolving the surface treatment in organic solvents, we process our proprietary filtration media through a patented supercritical-CO₂ process, protected under U.S. Patent No. 11,224,686 B2. The media is treated in a closed system, and the carbon dioxide is captured and reused, batch after batch, rather than released to the air or sent to a drain.

The CellNet™ routeSupercritical CO₂, in a closed system
  1. 01Media inOur proprietary filtration media
  2. 02ModifyPatented supercritical CO₂ process
  3. 03Media outReady for the filter, nothing to rinse
CO₂ captured and reused, batch after batch
  • No organic solvents
  • Zero process waterNot reduced, not recycled. None.
  • CO₂ recovered and reusedIn a closed loop
Figure 6The same job as Figure 1, with nothing to wash away. Protected under U.S. Patent No. 11,224,686 B2.

That is how we make the only whole blood leukoreduction filter in the world without organic solvents or wastewater, batch after batch, today. We stand behind that claim, and behind the invitation that comes with it: if another manufacturer can document an equivalent process, we would like to see it. Until then, that is where CellNet™ PR stands, and it is the work that has been recognized this year. Both award records independently describe the process as solvent-free and water-free.

Edison Awards 2026 SilverEdison Awards 2026Silver · Energy and Climate Resiliency
R&D 100 Awards 2026 WinnerR&D 100 Awards 2026Developed by Sangtech; joint work with the Taiwan Textile Research Institute

06Nothing was traded away

A cleaner process would be a footnote if it made a worse filter. It does not, and that is the part we are proudest of.

CellNet™ PR media in whole blood collection setsTop-tier filtration, nothing traded away
Residual white cells per unit<0.3×10⁶
Pre-storage standard 1×10⁶
Comfortably below the standard
Red cell recovery>92%
Platelet removal, carefully handling platelets to lower activation98–100%
ISO 10993-5 cytotoxicity grade0
  1. 0
  2. 1
  3. 2
  4. 3
  5. 4
The cleanest grade. No solvent, so no solvent residuals to extract.
Figure 7Performance band enabled by CellNet™ PR media, integrated into whole blood collection sets; residual white cells measured on fresh human whole blood (ISBT 2026). These are media results: finished-device performance and clearance rest with the integrating manufacturer.

Platelets are taken out of the red cells and plasma cleanly, rather than ruptured and left to release their contents back into the very components the filter is meant to protect. And there is a quiet logic to the cytotoxicity result: a process that never uses solvents has none to leave behind.

Top-tier filtration and a process with no organic solvents and no process water, in the same filter. Not a trade-off between them, which is the assumption we set out to break.

07A cleaner material, inside and out

The same thinking runs through the materials. CellNet™ PR is offered with zero-DEHP housing, in both hard and soft casing formats, and DEHP-free media. DEHP is a phthalate plasticizer long used in PVC medical components; it can migrate into blood during storage and transfusion, and the European Union has set a 2030 sunset for its use in medical devices.

Housing, hard casingZero DEHPHousing, soft casingZero DEHPFilter mediaDEHP-free
2023EU Regulation 2023/2482Sets a sunset for DEHP in medical devices
TodayCellNet™ PRZero-DEHP housing, DEHP-free media
July 1, 2030DEHP sunsetFor medical devices in the EU
Figure 8A clean process matched by a clean material, ahead of the EU deadline.

Taking it out of both the housing and the media means the clean process is matched by a clean material, which is increasingly what blood services and their regulators are asking for.

08The upstream bet

A word on what we are, because it shapes everything above. We are a materials company. We make filter media and semi-finished filters, and we supply them to the device manufacturers who build the finished collection systems used in blood centers. The process and the performance are ours; the finished device, its regulatory clearance and its labeling belong to the manufacturers who integrate our media.

SangtechFilter media and semi-finished filters
Device manufacturersFinished collection systems, clearance and labeling
Blood servicesEvery unit collected with those sets
Figure 9Change how one part is made, and the benefit carries into every product built on it.

That is a deliberate place to stand. The largest reductions available to healthcare are upstream, in the components that everything else is built from. A leukoreduction filter is one of the most widely produced single-use parts in all of transfusion medicine. Change how that one part is made, and the benefit does not stay with us. It carries into every product built on top of it, and into the footprint of every service that uses them.

“For thirty years the leukocyte filter was treated as a solved problem. We did not accept that. We went back to how the filter is actually made, and it turns out you can take out the solvents and the water and end up with a better filter, not a worse one. CellNet™ is not one product. It is a cleaner way to make a whole category of them, and that is the direction this industry has to go.”

Tyler McConville, Deputy CEO, Sangtech Lab Inc.

09What is next

Measuring the carbon of a transfusion was the right first step, and the people who did it deserve credit for starting a conversation the field had avoided. The next step is to widen the lens: to count the whole device, including how it was made, and to give the blood services who buy it a cleaner option when they do.

We started with the filter.We went back to the fiber.We are not done.

About CellNet™ PR

CellNet™ is a trademark of Sangtech Lab Inc. CellNet™ PR filter media and semi-finished filters are supplied to medical device manufacturers for integration into finished devices; CellNet™ PR is not itself a finished medical device, and finished-device performance and clearance are the responsibility of the integrating manufacturer.

Press and integration inquiries

Use our contact form

Talk about integrating CellNet™ media

Sources

  1. Hibbs SP, Thomas S, Agarwal N, et al. What is the environmental impact of a blood transfusion? A life cycle assessment of transfusion services across England. Transfusion. 2024. doi:10.1111/trf.17786 Link (opens in a new tab)
  2. World Health Organization. Blood safety and availability, fact sheet. Link (opens in a new tab)
  3. CDP and Boston Consulting Group. Scope 3 Upstream: Big Challenges, Simple Remedies. June 2024. Link (opens in a new tab)
  4. Health Care Without Harm and Arup. Health care’s climate footprint. September 2019. Link (opens in a new tab)
  5. IFRS Foundation. IFRS S2 Climate-related Disclosures. 2023.
  6. Ellen MacArthur Foundation. A New Textiles Economy: Redesigning Fashion’s Future. 2017.
  7. Sangtech Lab Inc. Filter material and manufacturing method thereof. U.S. Patent No. 11,224,686 B2. January 18, 2022. Link (opens in a new tab)
  8. Commission Regulation (EU) 2023/2482, amending Annex XIV to REACH (DEHP in medical devices). Link (opens in a new tab)
  • Sustainability
  • Scope 3
  • CellNet™ PR
  • Manufacturing
Source 1

Hibbs SP, Thomas S, Agarwal N, et al. What is the environmental impact of a blood transfusion? A life cycle assessment of transfusion services across England. Transfusion. 2024. doi:10.1111/trf.17786

View source (opens in a new tab)
Source 2

World Health Organization. Blood safety and availability, fact sheet.

View source (opens in a new tab)
Source 3

CDP and Boston Consulting Group. Scope 3 Upstream: Big Challenges, Simple Remedies. June 2024.

View source (opens in a new tab)
Source 4

Health Care Without Harm and Arup. Health care’s climate footprint. September 2019.

View source (opens in a new tab)
Source 5

IFRS Foundation. IFRS S2 Climate-related Disclosures. 2023.

See all sources
Source 6

Ellen MacArthur Foundation. A New Textiles Economy: Redesigning Fashion’s Future. 2017.

See all sources
Source 7

Sangtech Lab Inc. Filter material and manufacturing method thereof. U.S. Patent No. 11,224,686 B2. January 18, 2022.

View source (opens in a new tab)
Source 8

Commission Regulation (EU) 2023/2482, amending Annex XIV to REACH (DEHP in medical devices).

View source (opens in a new tab)

Request the technical brochure

Our team will email it to you.

I work at a…
Interested in Optional